TREMFYA® (guselkumab) Successfully Treats Difficult Psoriasis Areas Interview with:

Andrew Blauvelt, M.D., M.B.A. President Oregon Medical Research Center 

Dr. Blauvelt

Andrew Blauvelt, M.D., M.B.A.
Oregon Medical Research Center What is the background for this study? What are the main findings? 

Response: This new paper focuses on treatment of psoriasis in classically difficult-to-treat areas of the body, which include the scalp, the palms/soles, and the fingernails.

We show that guselkumab, which is a new biologic therapy that selectively targets IL-23 (a key pro-inflammatory cytokine in psoriasis pathogenesis), works well in these areas affected by psoriasis.

More specifically, after 6 months of treatment with guselkumab, approximately 85%, 80%, and 60% of patients achieved complete or near complete clearance of psoriasis in their scalp, palms/soles, and fingernails, respectively. What should readers take away from your report?

Response: These new data will inform therapeutic decisions by clinicians when faced with psoriasis patients with disease in difficult-to-treat areas of the body


Foley P, Gordon K, Griffiths CEM, et al. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body RegionsA Secondary Analysis of 2 Randomized Clinical TrialsJAMA Dermatol.Published online May 16, 2018. doi:10.1001/jamadermatol.2018.0793 

[wysija_form id=”3″] 

The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.


Last Updated on May 30, 2018 by Marie Benz MD FAAD